首页> 美国卫生研究院文献>Drugs in RD >Efficacy of Switching from Infliximab to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events

【2h】

Efficacy of Switching from Infliximab to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events

机译：类风湿关节炎患者从英夫利昔单抗切换至皮下戈利木单抗控制疾病活动或不良事件的功效

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundSome rheumatoid arthritis (RA) patients initially respond to treatment with infliximab (IFX), but subsequently their responsiveness decreases.

机译：背景技术一些类风湿关节炎（RA）患者最初对英夫利昔单抗（IFX）的治疗有反应，但随后其反应性下降。

著录项

期刊名称 Drugs in RD
作者
Hiroki Wakabayashi; Hitoshi Inada; Yosuke Nishioka; Masahiro Hasegawa; Kusuki Nishioka; Akihiro Sudo;
展开▼
作者单位

展开▼
年(卷),期 2017(17),1
年度 2017
页码 233–239
总页数 7
原文格式 PDF
正文语种
中图分类药学;
关键词

相似文献

外文文献
中文文献
专利

1. Efficacy of Switching from Infliximab to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events [J] . Hiroki Wakabayashi, Hitoshi Inada, Yosuke Nishioka, Drugs in R&D . 2017,第1期

机译：类风湿关节炎患者从英夫利昔单抗切换至皮下戈利木单抗控制疾病活动或不良事件的功效
2. Erratum: Golimumab, a human anti-tumor necrosis factor monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis [J] . li id=au1Paul Emery li id=au2Roy M. Fleischmann li id=au3Larry W. Moreland li id=au4Elizabeth C. Hsia li id=au5Ingrid Strusberg li id=au6Patrick Durez li id=au7Peter Nash li id=au8Eric Jason B. Amante li id=au9Melvin Churchill li id=au10Won Park li id=au11Bernardo Antonio Pons-Estel li id=au12Mittie K. Doyle li id=au13Sudha Visvanathan li id=au14Weichun Xu li id=au15Mahboob U. Rahman Arthritis & Rheumatism . 2010,第9期

机译：勘误：Golimumab，一种人类抗肿瘤坏死因子单克隆抗体，每隔四周皮下注射一次未接受甲氨蝶呤的活动性类风湿性关节炎患者：三期，多中心，随机，双盲，安慰剂治疗二十三周的结果氨甲蝶呤前戈利木单抗作为早期治疗类风湿关节炎的一线治疗的对照研究
3. Golimumab, a Human Anti-Tumor Necrosis Factor alpha Monoclonal Antibody, Injected Subcutaneously Every Four Weeks in Methotrexate-Naive Patients With Active Rheumatoid Arthritis Twenty-Four-Week Results of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Golimumab Before Methotrexate as First-Line Therapy for Early-Onset Rheumatoid Arthritis (vol 60, pg 2272, 2009) [J] . Emery Arthritis and Rheumatism . 2010,第9期

机译：Golimumab是一种人类抗肿瘤坏死因子α单克隆抗体，每四周一次皮下注射纯净甲氨蝶呤的活动性类风湿性关节炎患者，III期，多中心，随机，双盲，安慰剂对照研究的二十四周结果甲氨tre呤之前戈利木单抗作为早期治疗类风湿关节炎的一线治疗方法的研究（第60卷，第2272页，2009年）
4. Human Antichimeric Antibodies to Infliximab and Infusion-Related Allergic Reactions in Patients with Rheumatoid Arthritis [C] . D. Wouters, S. Stapel, M. Vis, Collegium Internationale Allergologicum . 2007

机译：人的苯甲酸纤维化率和类风湿性关节炎患者的infumency相关过敏反应的抗体抗体
5. The Efficacy of Therapeutic Drug Monitoring of Rheumatoid Arthritis Patients on Infliximab [D] . Abolhosn, Rania. 2018

机译：类风湿性关节炎患者治疗药物监测对英夫利昔单抗的疗效
6. Simultaneous Treatment with Subcutaneous Injection of Golimumab and Intra-articular Injection of Triamcinolone Acetonide (K-Method) in Patients with Rheumatoid Arthritis Undergoing Switching of Biologics: Retrospective Case–Control Study [O] . Katsuaki Kanbe, Junji Chiba, Yasuo Inoue, 2016

机译：皮下注射戈利木单抗和关节腔内注射曲安奈德乙酰丙酮同时治疗（类风湿关节炎）的生物制剂转换患者：回顾性病例对照研究
7. Efficacy of Switching from Infliximab to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events [O] . 2017

机译：类风湿关节炎患者从英夫利昔单抗切换至皮下戈利木单抗控制疾病活动或不良事件的功效

Efficacy of Switching from Infliximab to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events

摘要

著录项

相似文献

相关主题

期刊订阅